UVA Licensing & Ventures Group

Nanochon is developing an implantable, 3D-printed cartilage implant designed to replace damaged cartilage and promote new tissue growth in joints, with a focus on knee damage. The device combines 3D printing and a novel nanomaterial to enable on-demand, cost-effective solutions intended to restore joint function and improve outcomes for young and active patients.

BrightSpec specializes in innovative analytical chemistry services, utilizing its proprietary Fourier transform molecular rotational resonance (FT-MRR) technology. Based in Charlottesville, Virginia, the company delivers immediate results to clients, addressing high-value, time-sensitive challenges not well served by other spectroscopy techniques. Its platform offers configurations for manufacturing process control, quality control, environmental monitoring, and formulation research.

Utrain develops an all-in-one software solution for basketball training. It enables trainers to manage bookings, payments, and communication effectively, while providing a secure marketplace for athletes and parents to connect with trainers.

GenEp, Inc. is a pre-clinical stage biotechnology company that focuses on developing therapies for rare genetic epilepsies and other treatment-resistant forms of epilepsy. The company leverages its intellectual property assets to create selective compounds aimed at modulating sodium and other ion channels associated with these conditions. By targeting specific mutations within these channels, GenEp seeks to enable medical professionals to develop effective treatment options tailored to meet the unique medical needs of patients suffering from these challenging disorders.

Nanochon is developing an implantable, 3D-printed cartilage implant designed to replace damaged cartilage and promote new tissue growth in joints, with a focus on knee damage. The device combines 3D printing and a novel nanomaterial to enable on-demand, cost-effective solutions intended to restore joint function and improve outcomes for young and active patients.

Mission Secure, Inc. is a cybersecurity firm specializing in the protection of operational technology and control systems for critical industries such as oil and gas, power, chemicals, and defense. Established in 2014 and headquartered in Charlottesville, Virginia, with additional offices in Houston, Texas, and Cheltenham, United Kingdom, the company has developed the MSi Platform, which provides comprehensive cyber defense solutions. This platform integrates features such as visibility, segmentation, protection, threat hunting, and incident response, thereby delivering robust security against cyber threats, supply chain risks, and insider attacks. Mission Secure’s offerings are designed to be user-friendly, allowing non-IT professionals to effectively manage and deploy cybersecurity measures, ensuring that essential operations remain safe and uninterrupted. The company has formed a strategic partnership with Comodo Cybersecurity to enhance its service capabilities.

Slate Bio is an immunotherapeutics development company focused on restoring the body's natural immunological response in autoimmune and inflammatory diseases. It develops therapies based on bifunctional cytokines to create a second, independent synergistic pathway characterized by tissue selectivity and enhanced pharmacodynamics, allowing for lower-dose treatments.

BrightSpec specializes in innovative analytical chemistry services, utilizing its proprietary Fourier transform molecular rotational resonance (FT-MRR) technology. Based in Charlottesville, Virginia, the company delivers immediate results to clients, addressing high-value, time-sensitive challenges not well served by other spectroscopy techniques. Its platform offers configurations for manufacturing process control, quality control, environmental monitoring, and formulation research.

Merand Pharmaceuticals develops a microRNA therapeutic to treat Peripheral Arterial Disease. Merand's therapeutic treats patients by promoting angiogenesis or the development of new blood vessels, which leads to restored blood flow, enabling doctors to stabilize functional blood vessels of patients to increase perfusion recovery and reduce inflammation.

Direct Spinal Therapeutics, Inc. operates in the healthcare industry focusing on biotechnology business. The company was incorporated in 2013 and is based in Charlottesville, Virginia.

Arrive Health delivers cost and coverage information to providers, care teams, and patients to improve access to affordable, high-quality care. The company compiles patient-specific cost data and coverage details to support informed decision-making and reduce friction across the care continuum. It develops integrated technologies that bring cost and coverage information into health system workflows, leveraging a network of payers, PBMs, vendors, and tools to alert providers to coverage restrictions, lower-cost alternatives, and location-based options. Founded in 2013 and based in Denver, Arrive Health focuses on enabling providers to identify affordable care paths and streamline patient financial conversations.

Mission Secure, Inc. is a cybersecurity firm specializing in the protection of operational technology and control systems for critical industries such as oil and gas, power, chemicals, and defense. Established in 2014 and headquartered in Charlottesville, Virginia, with additional offices in Houston, Texas, and Cheltenham, United Kingdom, the company has developed the MSi Platform, which provides comprehensive cyber defense solutions. This platform integrates features such as visibility, segmentation, protection, threat hunting, and incident response, thereby delivering robust security against cyber threats, supply chain risks, and insider attacks. Mission Secure’s offerings are designed to be user-friendly, allowing non-IT professionals to effectively manage and deploy cybersecurity measures, ensuring that essential operations remain safe and uninterrupted. The company has formed a strategic partnership with Comodo Cybersecurity to enhance its service capabilities.

510 Kardiac Devices provides novel cardiovascular devices intended to assist in cardiovascular surgical procedures. Their intuitive platform provides physicians with an increased level of device control, functionality, and visibility. These features will make transseptal punctures more effective and efficient to perform and minimize costly complications. 510 Kardiac Devices is headquartered in Mableton, Georgia.

TearSolutions is a biotechnology company focused on developing Lacripep, a synthetic fragment of lacritin, as a topical therapy for dry eye. The treatment uses a short, stable peptide designed to preserve the activity of a natural tear protein, restore basal tearing, and promote corneal surface healing. It targets patients with dry eye symptoms, including those associated with primary Sjögren's syndrome. The company aims to advance Lacripep through clinical development as a replacement therapy for dry eye and has pursued phase II human clinical trials. Based in Charlottesville, Virginia, TearSolutions was founded in 2013.

TypeZero Technologies LLC is a healthcare technology company based in Charlottesville, Virginia, focused on diabetes management solutions. Incorporated in 2013, it has developed the inControl Diabetes Management Platform, which includes an innovative smartphone-based artificial pancreas that automates insulin delivery, significantly reduces the risk of hypoglycemia, and improves blood glucose levels. Additionally, the platform features inControl Advice, a mobile advisory system that provides real-time recommendations for meal planning, basal rates, bolus calculations, and exercise decisions. TypeZero also offers inControl Cloud, a suite of cloud-based tools that enable real-time monitoring and notifications for caregivers and family members, as well as retrospective data analysis to identify treatment inefficiencies. As of August 2018, TypeZero operates as a subsidiary of DexCom, Inc.